Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HEXCEL CORP /DE/
Report date May 04, 2017 · Filed May 05, 2017
Section 16 reporting ended · disclosed 2017-05-05. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2017 Filed Feb 16, 2017 23:56 UTC | HEXCEL CORP /DE/ HXL · Entity 3705 | GrantRestricted Stock Units · Derivative | 4.96 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-002586 · edgar.xml · derivative · entry 1 Hill David Charles · CIK 0001410674 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,397.96 Underlying: Common Stock · 4.96 shares Expires not disclosed F1 · security: The underlying Restricted Stock Units ("RSUs") were granted in a transaction exempt under Rule 16b. Upon vesting, RSUs are converted into an equivalent number of shares of Common Stock that are distributed to the grantee. F1 · derivative.exercise_price: The underlying Restricted Stock Units ("RSUs") were granted in a transaction exempt under Rule 16b. Upon vesting, RSUs are converted into an equivalent number of shares of Common Stock that are distributed to the grantee. F2 · shares: As previously reported, on May 5, 2016, the reporting person was granted 2,382 RSUs. Dividend equivalent rights accrue with respect to the unvested RSUs when and as dividends are paid on Hexcel common stock. The 4.96 dividend equivalent rights reflect dividend equivalent rights at $53.08 per RSU owned by the reporting person on the record date and credited to the reporting person's account on February 15, 2017. F1 · price: The underlying Restricted Stock Units ("RSUs") were granted in a transaction exempt under Rule 16b. Upon vesting, RSUs are converted into an equivalent number of shares of Common Stock that are distributed to the grantee. F3 · derivative.exercise_date: The underlying RSUs vest ratably over the one year period following the grant date and convert into an equivalent number of shares of Common Stock on the first anniversary of the grant date. Vesting of the RSUs was also subject to certain acceleration and termination provisions. F3 · derivative.expiration_date: The underlying RSUs vest ratably over the one year period following the grant date and convert into an equivalent number of shares of Common Stock on the first anniversary of the grant date. Vesting of the RSUs was also subject to certain acceleration and termination provisions. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 22:40 UTC | HEXCEL CORP /DE/ HXL · Entity 3705 | GrantRestricted Stock Units · Derivative | 5.5 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-031409 · edgar.xml · derivative · entry 1 Hill David Charles · CIK 0001410674 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,393.46 Underlying: Common Stock · 5.5 shares Expires not disclosed F1 · security: The underlying Restricted Stock Units ("RSUs") were granted in a transaction exempt under Rule 16b. Upon vesting, RSUs are converted into an equivalent number of shares of Common Stock that are distributed to the grantee. F1 · derivative.exercise_price: The underlying Restricted Stock Units ("RSUs") were granted in a transaction exempt under Rule 16b. Upon vesting, RSUs are converted into an equivalent number of shares of Common Stock that are distributed to the grantee. F2 · shares: As previously reported, on May 5, 2016, the reporting person was granted 2,382 RSUs. Dividend equivalent rights accrue with respect to the unvested RSUs when and as dividends are paid on Hexcel common stock. The 5.50 dividend equivalent rights reflect dividend equivalent rights at $47.73 per RSU owned by the reporting person on the record date and credited to the reporting person's account on November 9, 2016. F1 · price: The underlying Restricted Stock Units ("RSUs") were granted in a transaction exempt under Rule 16b. Upon vesting, RSUs are converted into an equivalent number of shares of Common Stock that are distributed to the grantee. F3 · derivative.exercise_date: The underlying RSUs vest ratably over the one year period following the grant date and convert into an equivalent number of shares of Common Stock on the first anniversary of the grant date. Vesting of the RSUs was also subject to certain acceleration and termination provisions. F3 · derivative.expiration_date: The underlying RSUs vest ratably over the one year period following the grant date and convert into an equivalent number of shares of Common Stock on the first anniversary of the grant date. Vesting of the RSUs was also subject to certain acceleration and termination provisions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.